Literature DB >> 20646841

Influence of noncompliance with radiation therapy protocol guidelines and operative bed recurrences for children with rhabdomyosarcoma and microscopic residual disease: a report from the Children's Oncology Group.

Lynn Million1, James Anderson, John Breneman, Douglas S Hawkins, Fran Laurie, Jeff Michalski, David Rodeberg, Moody Wharam, Suzanne Wolden, Sarah S Donaldson.   

Abstract

PURPOSE: Postoperative radiation therapy (RT) is recommended for patients with rhabdomyosarcoma having microscopic disease. Sometimes RT dose/volume is reduced or omitted in an attempt to avoid late effects, particularly in young children. We reviewed operative bed recurrences to determine if noncompliance with RT protocol guidelines influenced local-regional control. METHODS AND MATERIALS: All operative bed recurrences among 695 Group II rhabdomyosarcoma patients in Intergroup Rhabdomyosarcoma Study Group (IRS) I through IV were reviewed for deviation from RT protocol. Major/minor dose deviation was defined as >10% or 6-10% of the prescribed dose (40-60 Gy), respectively. Major/minor volume deviation was defined as tumor excluded from the RT field or treatment volume not covered by the specified margin (preoperative tumor volume and 2- to 5-cm margin), respectively. No RT was a major deviation.
RESULTS: Forty-six of 83 (55%) patients with operative bed recurrences did not receive the intended RT (39 major and 7 minor deviations). RT omission was the most frequent RT protocol deviation (19/46, 41%), followed by dose (17/46, 37%), volume (9/46, 20%), and dose and volume deviation (1/46, 2%). Only 7 operative bed recurrences occurred in IRS IV (5% local-regional failure) with only 3 RT protocol deviations. Sixty-three (76%) patients with recurrence died of disease despite retrieval therapy, including 13 of 19 nonirradiated children.
CONCLUSION: Over half of the operative bed recurrences were associated with noncompliance; omission of RT was the most common protocol deviation. Three fourths of children die when local-regional disease is not controlled, emphasizing the importance of RT in Group II rhabdomyosarcoma.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20646841      PMCID: PMC4462166          DOI: 10.1016/j.ijrobp.2010.01.058

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  15 in total

1.  Benefit of intensified therapy for patients with local or regional embryonal rhabdomyosarcoma: results from the Intergroup Rhabdomyosarcoma Study IV.

Authors:  K S Baker; J R Anderson; M P Link; H E Grier; S J Qualman; H M Maurer; J C Breneman; E S Wiener; W M Crist
Journal:  J Clin Oncol       Date:  2000-06       Impact factor: 44.544

2.  Survival after relapse in children and adolescents with rhabdomyosarcoma: A report from the Intergroup Rhabdomyosarcoma Study Group.

Authors:  A S Pappo; J R Anderson; W M Crist; M D Wharam; P P Breitfeld; D Hawkins; R B Raney; R B Womer; D M Parham; S J Qualman; H E Grier
Journal:  J Clin Oncol       Date:  1999-11       Impact factor: 44.544

3.  Which patients with microscopic disease and rhabdomyosarcoma experience relapse after therapy? A report from the soft tissue sarcoma committee of the children's oncology group.

Authors:  L M Smith; J R Anderson; S J Qualman; W M Crist; C N Paidas; L A Teot; A S Pappo; M P Link; H E Grier; E S Wiener; J C Breneman; R B Raney; H M Maurer; S S Donaldson
Journal:  J Clin Oncol       Date:  2001-10-15       Impact factor: 44.544

4.  Initial patient characteristics can predict pattern and risk of relapse in localized rhabdomyosarcoma.

Authors:  Tobias M Dantonello; Christoph Int-Veen; Peter Winkler; Ivo Leuschner; Andreas Schuck; Bernhard F Schmidt; Helmut Lochbuehler; Sylvia Kirsch; Erika Hallmen; Iris Veit-Friedrich; Stefan S Bielack; Felix Niggli; Bernarda Kazanowska; Ruth Ladenstein; Thomas Wiebe; Thomas Klingebiel; Joern Treuner; Ewa Koscielniak
Journal:  J Clin Oncol       Date:  2008-01-20       Impact factor: 44.544

5.  The Intergroup Rhabdomyosarcoma Study-II.

Authors:  H M Maurer; E A Gehan; M Beltangady; W Crist; P S Dickman; S S Donaldson; C Fryer; D Hammond; D M Hays; J Herrmann
Journal:  Cancer       Date:  1993-03-01       Impact factor: 6.860

6.  An evaluation of the relationship between the quality of prophylactic cranial radiotherapy in childhood acute leukemia and institutional experience: a Quality Assurance Review Center-Pediatric Oncology Group study.

Authors:  Edward C Halperin; Fran Laurie; T J Fitzgerald
Journal:  Int J Radiat Oncol Biol Phys       Date:  2002-07-15       Impact factor: 7.038

7.  The Intergroup Rhabdomyosarcoma Study-I. A final report.

Authors:  H M Maurer; M Beltangady; E A Gehan; W Crist; D Hammond; D M Hays; R Heyn; W Lawrence; W Newton; J Ortega
Journal:  Cancer       Date:  1988-01-15       Impact factor: 6.860

8.  A multidisciplinary study investigating radiotherapy in Ewing's sarcoma: end results of POG #8346. Pediatric Oncology Group.

Authors:  S S Donaldson; M Torrey; M P Link; A Glicksman; L Gilula; F Laurie; J Manning; J Neff; W Reinus; E Thompson; J J Shuster
Journal:  Int J Radiat Oncol Biol Phys       Date:  1998-08-01       Impact factor: 7.038

9.  The Intergroup Rhabdomyosarcoma Study Group (IRSG): Major Lessons From the IRS-I Through IRS-IV Studies as Background for the Current IRS-V Treatment Protocols.

Authors:  R B Raney; H M Maurer; J R Anderson; R J Andrassy; S S Donaldson; S J Qualman; M D Wharam; E S Wiener; W M Crist
Journal:  Sarcoma       Date:  2001

10.  Image quality & dosimetric property of an investigational imaging beam line MV-CBCT.

Authors:  Chris Beltran; Renin Lukose; Bijumon Gangadharan; Ali Bani-Hashemi; Bruce A Faddegon
Journal:  J Appl Clin Med Phys       Date:  2009-06-17       Impact factor: 2.102

View more
  13 in total

Review 1.  Progress in radiotherapy for pediatric sarcomas.

Authors:  Susan L McGovern; Anita Mahajan
Journal:  Curr Oncol Rep       Date:  2012-08       Impact factor: 5.075

2.  Rhabdomyosarcoma in infants younger than 1 year: a report from the Children's Oncology Group.

Authors:  Suman Malempati; David A Rodeberg; Sarah S Donaldson; Elizabeth R Lyden; James R Anderson; Douglas S Hawkins; Carola A S Arndt
Journal:  Cancer       Date:  2011-01-24       Impact factor: 6.860

Review 3.  Radiotherapy protocol deviations and clinical outcomes: a meta-analysis of cooperative group clinical trials.

Authors:  Nitin Ohri; Xinglei Shen; Adam P Dicker; Laura A Doyle; Amy S Harrison; Timothy N Showalter
Journal:  J Natl Cancer Inst       Date:  2013-03-06       Impact factor: 13.506

4.  Treatment Approach and Outcomes in Infants With Localized Rhabdomyosarcoma: A Report From the Soft Tissue Sarcoma Committee of the Children's Oncology Group.

Authors:  Julie A Bradley; Mark L Kayton; Yueh-Yun Chi; Douglas S Hawkins; Jing Tian; John Breneman; Suzanne L Wolden; David Walterhouse; David A Rodeberg; Sarah S Donaldson
Journal:  Int J Radiat Oncol Biol Phys       Date:  2018-08-20       Impact factor: 7.038

5.  Local control with reduced-dose radiotherapy for low-risk rhabdomyosarcoma: a report from the Children's Oncology Group D9602 study.

Authors:  John Breneman; Jane Meza; Sarah S Donaldson; R Beverly Raney; Suzanne Wolden; Jeff Michalski; Fran Laurie; David A Rodeberg; William Meyer; David Walterhouse; Douglas S Hawkins
Journal:  Int J Radiat Oncol Biol Phys       Date:  2011-11-19       Impact factor: 7.038

6.  Do children and adolescents with completely resected alveolar rhabdomyosarcoma require adjuvant radiation? A report from the Children's Oncology Group.

Authors:  Jamie M Aye; Yueh-Yun Chi; Jing Tian; Erin R Rudzinski; Odion T Binitie; Roshni Dasgupta; Suzanne L Wolden; Douglas S Hawkins; Abha A Gupta
Journal:  Pediatr Blood Cancer       Date:  2020-03-02       Impact factor: 3.167

7.  Delayed primary excision with subsequent modification of radiotherapy dose for intermediate-risk rhabdomyosarcoma: a report from the Children's Oncology Group Soft Tissue Sarcoma Committee.

Authors:  David A Rodeberg; Moody D Wharam; Elizabeth R Lyden; Julie A Stoner; Kenneth Brown; Suzanne L Wolden; Charles N Paidas; Sarah S Donaldson; Douglas S Hawkins; Sheri L Spunt; Carola A Arndt
Journal:  Int J Cancer       Date:  2014-12-10       Impact factor: 7.396

Review 8.  What is new in the biology and treatment of pediatric rhabdomyosarcoma?

Authors:  Douglas S Hawkins; Abha A Gupta; Erin R Rudzinski
Journal:  Curr Opin Pediatr       Date:  2014-02       Impact factor: 2.856

Review 9.  Children's Oncology Group's 2013 blueprint for research: Soft tissue sarcomas.

Authors:  Douglas S Hawkins; Sheri L Spunt; Stephen X Skapek
Journal:  Pediatr Blood Cancer       Date:  2012-12-19       Impact factor: 3.167

10.  Compliance with therapeutic guidelines in Radiation Therapy Oncology Group prospective gastrointestinal clinical trials.

Authors:  Christopher G Willett; Jennifer Moughan; Elizabeth O'Meara; James M Galvin; Christopher H Crane; Kathryn Winter; Denise Manfredi; Tyvin A Rich; Rachel Rabinovitch; Robert Lustig; Mitchell Machtay; Walter J Curran
Journal:  Radiother Oncol       Date:  2012-10-17       Impact factor: 6.280

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.